X4 Pharmaceuticals (XFOR) Competitors $0.19 0.00 (-2.30%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.20 +0.01 (+7.44%) As of 04/17/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XFOR vs. FULC, DERM, ACRS, IPHA, MOLN, PBYI, KRRO, CTNM, RAPT, and TNGXShould you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include Fulcrum Therapeutics (FULC), Journey Medical (DERM), Aclaris Therapeutics (ACRS), Innate Pharma (IPHA), Molecular Partners (MOLN), Puma Biotechnology (PBYI), Korro Bio (KRRO), Contineum Therapeutics (CTNM), RAPT Therapeutics (RAPT), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry. X4 Pharmaceuticals vs. Fulcrum Therapeutics Journey Medical Aclaris Therapeutics Innate Pharma Molecular Partners Puma Biotechnology Korro Bio Contineum Therapeutics RAPT Therapeutics Tango Therapeutics Fulcrum Therapeutics (NASDAQ:FULC) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation, community ranking and earnings. Is FULC or XFOR more profitable? Fulcrum Therapeutics' return on equity of -7.31% beat X4 Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -7.31% -6.74% X4 Pharmaceuticals N/A -236.19%-75.14% Does the MarketBeat Community prefer FULC or XFOR? Fulcrum Therapeutics received 19 more outperform votes than X4 Pharmaceuticals when rated by MarketBeat users. However, 68.10% of users gave X4 Pharmaceuticals an outperform vote while only 60.87% of users gave Fulcrum Therapeutics an outperform vote. CompanyUnderperformOutperformFulcrum TherapeuticsOutperform Votes9860.87% Underperform Votes6339.13% X4 PharmaceuticalsOutperform Votes7968.10% Underperform Votes3731.90% Do analysts recommend FULC or XFOR? Fulcrum Therapeutics currently has a consensus price target of $8.63, suggesting a potential upside of 162.16%. X4 Pharmaceuticals has a consensus price target of $2.83, suggesting a potential upside of 1,384.98%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11X4 Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, FULC or XFOR? Fulcrum Therapeutics has higher revenue and earnings than X4 Pharmaceuticals. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum Therapeutics$80M2.22-$97.33M-$0.22-14.95X4 Pharmaceuticals$2.56M12.96-$101.17M-$0.19-1.00 Which has more risk and volatility, FULC or XFOR? Fulcrum Therapeutics has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Does the media favor FULC or XFOR? In the previous week, Fulcrum Therapeutics had 2 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 2 mentions for Fulcrum Therapeutics and 0 mentions for X4 Pharmaceuticals. Fulcrum Therapeutics' average media sentiment score of 0.50 beat X4 Pharmaceuticals' score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Fulcrum Therapeutics Positive X4 Pharmaceuticals Neutral Do insiders & institutionals have more ownership in FULC or XFOR? 89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 4.1% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 1.6% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryFulcrum Therapeutics beats X4 Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XFOR vs. The Competition Export to ExcelMetricX4 PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.14M$2.84B$5.30B$7.34BDividend YieldN/A1.86%5.12%4.30%P/E Ratio-2.1230.4821.8017.78Price / Sales12.96441.91379.9697.74Price / CashN/A168.6838.2634.64Price / Book0.623.466.443.97Net Income-$101.17M-$72.06M$3.21B$247.65M7 Day Performance-9.14%2.56%2.85%1.80%1 Month Performance-35.23%-15.70%-8.64%-6.98%1 Year Performance-84.10%-26.10%11.38%1.34% X4 Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XFORX4 Pharmaceuticals4.2742 of 5 stars$0.19-2.3%$2.83+1,385.0%-84.0%$33.14M$2.56M-2.1280FULCFulcrum Therapeutics2.0065 of 5 stars$2.72+8.4%$8.63+217.1%-54.0%$146.82M$80M-8.77100Short Interest ↓News CoveragePositive NewsDERMJourney Medical2.213 of 5 stars$6.96-3.2%$9.88+41.9%+61.9%$145.39M$56.13M-7.4090Short Interest ↑High Trading VolumeACRSAclaris Therapeutics1.8451 of 5 stars$1.33-5.0%$11.67+777.2%-7.3%$143.53M$18.72M-2.56100Gap DownIPHAInnate Pharma1.9789 of 5 stars$1.71-6.6%$11.50+572.5%-17.9%$143.35M$12.63M0.00220Gap DownMOLNMolecular Partners1.6147 of 5 stars$3.54-0.8%$12.00+239.0%+1.5%$142.93M$4.97M-1.65180PBYIPuma Biotechnology3.3393 of 5 stars$2.83-2.4%$7.00+147.3%-44.7%$140.40M$230.47M5.90200Analyst UpgradeKRROKorro Bio1.3813 of 5 stars$14.93+3.8%$136.33+813.2%-79.9%$140.18M$2.27M-1.5970Analyst ForecastNews CoveragePositive NewsGap UpCTNMContineum Therapeutics2.1551 of 5 stars$5.37-7.4%$24.80+361.8%-70.0%$138.93M$50M-1.1031Positive NewsGap DownRAPTRAPT Therapeutics3.6138 of 5 stars$1.05-0.9%$4.00+281.0%-90.2%$138.61M$1.53M-0.3880Short Interest ↑News CoverageTNGXTango Therapeutics2.0927 of 5 stars$1.27flat$12.33+871.1%-82.7%$137.30M$42.07M-1.0890Analyst RevisionNews CoveragePositive NewsGap Down Related Companies and Tools Related Companies FULC Competitors DERM Competitors ACRS Competitors IPHA Competitors MOLN Competitors PBYI Competitors KRRO Competitors CTNM Competitors RAPT Competitors TNGX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XFOR) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XFOR Stock Free XFOR Stock Alerts